Description
Efaroxan hydrochloride is an antagonist at α2-adrenergic receptors and imidazoline-1 receptors. Efaroxan hydrochloride administration in animal models of opioid use shows a potential role for α2-adrenergic receptors in opioid-mediated mechanisms of tolerance and antinociception. This compound also exhibits antihyperglycemic activity, improving oral glucose tolerance in animal models of diabetes due to its ability to inhibit K(ATP) K+ channels on pancreatic beta cells. Additionally, administration of efaroxan hydrochloride shows benefit in animal models of Parkinson’s Disease.